Back to search

Netherlands· NL-92418ae6865d

Livtencity 200 mg, filmomhulde tabletten

A maribavir product containing maribavir, registered in Netherlands by Shire Pharmaceuticals Ireland Limited. The same ATC class is registered in 15 of our 19 countries.

ATC J05AX10

Checked against CBG-MEB (Netherlands) on

Informational only — not a medical device.

SOURCE REGISTER · NLCBG-MEB (Netherlands)normalisedLivtencity 200 mg, filmomhulde tablet…ATCJ05AX10REGISTER NO.NL-92418ae6865dPACKS LISTED1CHECKEDSeptember 29, 2026

Where it is registered

Maribavir is registered in 15 of 19 countries.

Countries holding a registration under ATC J05AX10 (maribavir), each read from that country’s own register.

  • This record: Netherlands, from CBG-MEB (Netherlands)
  • 10 of them publish a price we can compare per daily dose

Maribavir · ATC J05AX10

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Italyprice
  • Netherlands
  • Norwayprice
  • Polandprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of maribavir costs, country by country.

Normalised to the WHO defined daily dose (0.8 g), the median price runs from $0.94 in France to $1342.12 in Italy — a ×1425 gap.

  • 3 markets with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Maribavir · price per daily dose (0.8 g)

USD · FX 28 Sept 2026

  • IT Italy$1342.12
  • CH Switzerland$975.13
  • FR France$0.94
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

CBG-MEB (Netherlands)
Active substance
MARIBAVIR
Manufacturer
Shire Pharmaceuticals Ireland Limited
Country
Netherlands (NL)
ATC code
J05AX10
ATC class
Maribavir
Defined daily dose
0.8 g, O
Reimbursed
Not published by this register
Source register
CBG-MEB (Netherlands)
Last checked
September 29, 2026

Packs & prices · 1

  • cbg_meb_id
    EU/1/22/1672

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of CBG-MEB (Netherlands). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/40b6f124-0d63-4b6a-bb5f-c7c163e5ba2a
GET /v1/drugs/40b6f124-0d63-4b6a-bb5f-c7c163e5ba2a?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Filmomhulde tablet",
  "route": "Oraal gebruik",
  "soort": null,
  "source": "cbg_meb",
  "smpc_url": "https://www.ema.europa.eu/en/documents/product-information/livtencity-epar-product-information_nl.pdf",
  "strength": null,
  "atc_label": "Maribavir",
  "detail_url": "https://www.geneesmiddeleninformatiebank.nl/nl/cp128479",
  "excipients": [
    "BRILJANTBLAUW FCF ALUMINIUMLAK (E133)",
    "CELLULOSE, MICROKRISTALLIJN (E 460(i))",
    "MACROGOL 3350",
    "MAGNESIUMSTEARAAT (E 470b)",
    "NATRIUMZETMEELGLYCOLAAT",
    "POLYVINYLALCOHOL (E 1203)",
    "TALK (E 553b)",
    "TITAANDIOXIDE (E 171)"
  ],
  "substances": [
    "MARIBAVIR"
  ],
  "leaflet_url": null,
  "authorised_at": "2022/11/09",
  "procedure_number": "EMEA/H/C/005787",
  "dispensing_status": "Uitsluitend recept",
  "registration_number": "EU/1/22/1672",
  "additional_monitoring": "Y"
}

See everything about maribavir.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.